| Treatment (no. of patients with data available) . | Whole population (n= 30 977) . | Men (n= 23 975) . | Women (n= 7002) . | P-valuea . |
|---|---|---|---|---|
| Lipid-lowering drug (n = 30 972) | 28 566 (92.2) | 22 262 (92.9) | 6304 (90.1) | <0.0001 |
| Statins (n = 30 972) | 25 638 (82.8) | 20 027 (83.5) | 5611 (80.2) | <0.0001 |
| Aspirin (n = 30 971) | 27 165 (87.7) | 21 073 (87.9) | 6092 (87.0) | 0.048 |
| Thienopyridine (n = 30 957) | 8201 (26.5) | 6431 (26.8) | 1770 (25.3) | 0.01 |
| Other antiplatelet agent (n = 30 957) | 2868 (9.3) | 2208 (9.2) | 660 (9.4) | 0.59 |
| Oral anticoagulant agent (n = 30 970) | 2548 (8.2) | 2055 (8.6) | 493 (7.0) | <0.0001 |
| ACE inhibitor and/or ARB (n = 30 969) | 23 543 (76.0) | 18 203 (75.9) | 5340 (76.3) | 0.54 |
| Beta-blocker (n = 30 972) | 23 299 (75.2) | 18 047 (75.3) | 5252 (75.0) | 0.66 |
| Diuretic (n = 30 969) | 9091 (29.4) | 6449 (26.9) | 2642 (37.7) | <0.0001 |
| Calcium channel blocker (n = 30 967) | 8404 (27.1) | 6137 (25.6) | 2267 (32.4) | <0.0001 |
| Long-acting nitrate (n = 30 969) | 6837 (22.1) | 5028 (21.0) | 1809 (25.8) | <0.0001 |
| Ivabradine (n = 30 970) | 3120 (10.1) | 2313 (9.6) | 807 (11.5) | <0.0001 |
| Verapamil or diltiazem (n = 30 967) | 1775 (5.7) | 1276 (5.3) | 499 (7.1) | <0.0001 |
| Other antianginal agent (n = 30 966) | 4403 (14.2) | 3192 (13.3) | 1211 (17.3) | <0.0001 |
| Treatment (no. of patients with data available) . | Whole population (n= 30 977) . | Men (n= 23 975) . | Women (n= 7002) . | P-valuea . |
|---|---|---|---|---|
| Lipid-lowering drug (n = 30 972) | 28 566 (92.2) | 22 262 (92.9) | 6304 (90.1) | <0.0001 |
| Statins (n = 30 972) | 25 638 (82.8) | 20 027 (83.5) | 5611 (80.2) | <0.0001 |
| Aspirin (n = 30 971) | 27 165 (87.7) | 21 073 (87.9) | 6092 (87.0) | 0.048 |
| Thienopyridine (n = 30 957) | 8201 (26.5) | 6431 (26.8) | 1770 (25.3) | 0.01 |
| Other antiplatelet agent (n = 30 957) | 2868 (9.3) | 2208 (9.2) | 660 (9.4) | 0.59 |
| Oral anticoagulant agent (n = 30 970) | 2548 (8.2) | 2055 (8.6) | 493 (7.0) | <0.0001 |
| ACE inhibitor and/or ARB (n = 30 969) | 23 543 (76.0) | 18 203 (75.9) | 5340 (76.3) | 0.54 |
| Beta-blocker (n = 30 972) | 23 299 (75.2) | 18 047 (75.3) | 5252 (75.0) | 0.66 |
| Diuretic (n = 30 969) | 9091 (29.4) | 6449 (26.9) | 2642 (37.7) | <0.0001 |
| Calcium channel blocker (n = 30 967) | 8404 (27.1) | 6137 (25.6) | 2267 (32.4) | <0.0001 |
| Long-acting nitrate (n = 30 969) | 6837 (22.1) | 5028 (21.0) | 1809 (25.8) | <0.0001 |
| Ivabradine (n = 30 970) | 3120 (10.1) | 2313 (9.6) | 807 (11.5) | <0.0001 |
| Verapamil or diltiazem (n = 30 967) | 1775 (5.7) | 1276 (5.3) | 499 (7.1) | <0.0001 |
| Other antianginal agent (n = 30 966) | 4403 (14.2) | 3192 (13.3) | 1211 (17.3) | <0.0001 |
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.
Values are numbers (percentages).
aMen vs. women.
| Treatment (no. of patients with data available) . | Whole population (n= 30 977) . | Men (n= 23 975) . | Women (n= 7002) . | P-valuea . |
|---|---|---|---|---|
| Lipid-lowering drug (n = 30 972) | 28 566 (92.2) | 22 262 (92.9) | 6304 (90.1) | <0.0001 |
| Statins (n = 30 972) | 25 638 (82.8) | 20 027 (83.5) | 5611 (80.2) | <0.0001 |
| Aspirin (n = 30 971) | 27 165 (87.7) | 21 073 (87.9) | 6092 (87.0) | 0.048 |
| Thienopyridine (n = 30 957) | 8201 (26.5) | 6431 (26.8) | 1770 (25.3) | 0.01 |
| Other antiplatelet agent (n = 30 957) | 2868 (9.3) | 2208 (9.2) | 660 (9.4) | 0.59 |
| Oral anticoagulant agent (n = 30 970) | 2548 (8.2) | 2055 (8.6) | 493 (7.0) | <0.0001 |
| ACE inhibitor and/or ARB (n = 30 969) | 23 543 (76.0) | 18 203 (75.9) | 5340 (76.3) | 0.54 |
| Beta-blocker (n = 30 972) | 23 299 (75.2) | 18 047 (75.3) | 5252 (75.0) | 0.66 |
| Diuretic (n = 30 969) | 9091 (29.4) | 6449 (26.9) | 2642 (37.7) | <0.0001 |
| Calcium channel blocker (n = 30 967) | 8404 (27.1) | 6137 (25.6) | 2267 (32.4) | <0.0001 |
| Long-acting nitrate (n = 30 969) | 6837 (22.1) | 5028 (21.0) | 1809 (25.8) | <0.0001 |
| Ivabradine (n = 30 970) | 3120 (10.1) | 2313 (9.6) | 807 (11.5) | <0.0001 |
| Verapamil or diltiazem (n = 30 967) | 1775 (5.7) | 1276 (5.3) | 499 (7.1) | <0.0001 |
| Other antianginal agent (n = 30 966) | 4403 (14.2) | 3192 (13.3) | 1211 (17.3) | <0.0001 |
| Treatment (no. of patients with data available) . | Whole population (n= 30 977) . | Men (n= 23 975) . | Women (n= 7002) . | P-valuea . |
|---|---|---|---|---|
| Lipid-lowering drug (n = 30 972) | 28 566 (92.2) | 22 262 (92.9) | 6304 (90.1) | <0.0001 |
| Statins (n = 30 972) | 25 638 (82.8) | 20 027 (83.5) | 5611 (80.2) | <0.0001 |
| Aspirin (n = 30 971) | 27 165 (87.7) | 21 073 (87.9) | 6092 (87.0) | 0.048 |
| Thienopyridine (n = 30 957) | 8201 (26.5) | 6431 (26.8) | 1770 (25.3) | 0.01 |
| Other antiplatelet agent (n = 30 957) | 2868 (9.3) | 2208 (9.2) | 660 (9.4) | 0.59 |
| Oral anticoagulant agent (n = 30 970) | 2548 (8.2) | 2055 (8.6) | 493 (7.0) | <0.0001 |
| ACE inhibitor and/or ARB (n = 30 969) | 23 543 (76.0) | 18 203 (75.9) | 5340 (76.3) | 0.54 |
| Beta-blocker (n = 30 972) | 23 299 (75.2) | 18 047 (75.3) | 5252 (75.0) | 0.66 |
| Diuretic (n = 30 969) | 9091 (29.4) | 6449 (26.9) | 2642 (37.7) | <0.0001 |
| Calcium channel blocker (n = 30 967) | 8404 (27.1) | 6137 (25.6) | 2267 (32.4) | <0.0001 |
| Long-acting nitrate (n = 30 969) | 6837 (22.1) | 5028 (21.0) | 1809 (25.8) | <0.0001 |
| Ivabradine (n = 30 970) | 3120 (10.1) | 2313 (9.6) | 807 (11.5) | <0.0001 |
| Verapamil or diltiazem (n = 30 967) | 1775 (5.7) | 1276 (5.3) | 499 (7.1) | <0.0001 |
| Other antianginal agent (n = 30 966) | 4403 (14.2) | 3192 (13.3) | 1211 (17.3) | <0.0001 |
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.
Values are numbers (percentages).
aMen vs. women.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
